- Conditions
- Hepatitis C, Chronic
- Interventions
- Not listed
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 570 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 158
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 89 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 901
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Opioid-Related Disorders, Hepatitis C (HCV), Human Immunodeficiency Virus (HIV), Drug Overdose, Substance Abuse, Intravenous Drug Usage, Opiate Substitution Treatment, Sexually Transmitted Diseases
- Interventions
- Health kiosk
- Behavioral
- Lead sponsor
- April M Young
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 752 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Hepatitis C, Chronic
- Interventions
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus], Pioglitazone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 53 more
- Conditions
- Hepatitis C
- Interventions
- TMC435, Ribavirin (R), PegIFNα-2a (P), Placebo
- Drug
- Lead sponsor
- Tibotec Pharmaceuticals, Ireland
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 9 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo
- Drug · Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 85
- States / cities
- Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
- Conditions
- Hepatitis C, Hepatitis C, Chronic, HIV/AIDS
- Interventions
- Not listed
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Hepatitis C
- Interventions
- Glecaprevir/pibrentasvir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 16 Years to 45 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Aurora, Colorado • Jacksonville, Florida + 5 more
- Conditions
- Hepatic Encephalopathy, Hepatitis C, Liver Cirrhosis
- Interventions
- Rifaximin (drug)
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HCV
- Interventions
- Not listed
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Houston, Texas
- Conditions
- HEPATITIS C VIRUS CHRONIC INFECTION
- Interventions
- Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (SOF/VEL)
- Drug
- Lead sponsor
- Atea Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 880 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 96
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 84 more
- Conditions
- Hepatitis C
- Interventions
- Daclatasvir, Sofosbuvir, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Miami, Florida • Ann Arbor, Michigan • Houston, Texas + 2 more
- Conditions
- PTSD
- Interventions
- Glecaprevir / Pibrentasvir Pill
- Drug
- Lead sponsor
- White River Junction Veterans Affairs Medical Center
- Federal
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- White River Junction, Vermont
- Conditions
- Hepatitis C, Chronic
- Interventions
- Telaprevir, pegylated interferon (Peg-IFN) alfa-2a, ribavirin (RBV)
- Drug
- Lead sponsor
- Janssen Infectious Diseases BVBA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 14
- States / cities
- Coronado, California • Los Angeles, California • San Francisco, California + 11 more
- Conditions
- Hepatitis C
- Interventions
- VX-950, ribavirin, peginterferon alfa-2a
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hepatitis C, Depression
- Interventions
- Depression collaborative care model
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 4
- States / cities
- Little Rock, Arkansas • West Los Angeles, California • St Louis, Missouri + 1 more
- Conditions
- Hepatitis C
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hepatitis C, Hemodialysis, Nosocomial Infection
- Interventions
- Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Alcoholism, Alcohol Abuse, Hepatitis C, Liver Disease
- Interventions
- 3 session brief intervention with health behavior feedback, treatment as usual
- Behavioral · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hepatitis C, Renal Cell Carcinoma, Colorectal Cancer
- Interventions
- Hepatitis C testing
- Other
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Hepatitis C, Opioid-Related Disorders
- Interventions
- telaprevir, buprenorphine/naloxone
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 2
- States / cities
- Overland Park, Kansas • Salt Lake City, Utah
- Conditions
- Chronic Hepatitis C
- Interventions
- Omega DUROS device
- Drug
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • St Louis, Missouri + 4 more
- Conditions
- HIV Infections, Hepatitis C
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 42
- States / cities
- Los Angeles, California • Menlo Park, California • San Diego, California + 27 more
- Conditions
- HIV Infections, Sexually Transmitted Diseases, Bacterial, Hepatitis C, Substance Use Disorders
- Interventions
- Mobile Enhanced Prevention Support, Usual Care plus Customized Referrals
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 49 Years · Male only
- Enrollment
- 233 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Santa Fe Springs, California
- Conditions
- Hepatitis C, Chronic
- Interventions
- Epclusa (SOF/VEL), Standard of care, Fibroscan® 430 Mini Plus
- Drug · Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California